CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 131.48% from the […]